Study identifier:D1843R00243
ClinicalTrials.gov identifier:NCT02355145
EudraCT identifier:N/A
CTIS identifier:N/A
REALITY: A non-inteRvEntional study to observe the rAtionaLe of selectIng add-on TherapY for type 2 diabetes inadequately controlled with metformin in real-life practice at 1 year distance
Type 2 Diabetes Mellitus
N/A
No
-
All
1005
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 May 2017 by AstraZeneca
AstraZeneca
-
A non-interventional, multicentre study to observe the main criteria used in clinical practice by physicians when selecting the second-line add-on therapy in patients with inadequately metformin-controlled type 2 diabetes in 2 time points at 1 year distance. Data will be collected by reviewing the medical records of patients with type 2 diabetes and add-on therapies at the time of presenting to endocrinologist according to clinical practice. The patients will participate in only one study visit, at the time of enrolment. Two study groups are to be defined at two time-points.
A non-interventional, multicenter study to observe the main criteria used in clinical practice by physicians when selecting the second-line add-on therapy in patients with inadequately metformin-controlled type 2 diabetes in 2 time points at 1 year distance. The study will enrol a minimum of 500 patients in each time point, resulting in a total of at least 1000 from approximately 50 investigators from Bulgaria. Each investigator will recruit approximately 10 subjects. The assignment of the patients to a particular add-on therapy is not decided in advance by the NIS protocol, but falls within current practice and the prescription of medicine is clearly separated from the decision to include the subject in the study. No additional diagnostic and monitoring procedures shall be applied to patients, other than daily clinical practice and the epidemiological methods shall be used for the analysis of collected data. The intention of the study is to collect data on patients with type 2 diabetes and add-on therapies under routine clinical care. The patients will participate in only one study visit, at the time of enrolment, when they provide the written informed consent, thus allowing the access to their data. Data will be collected by reviewing the medical records of patients. Two study groups are to be defined at each time-point – one study group enrolled in moment 1 of evaluation (Feb – Mar 2015) and one study group enrolled in moment 2 of evaluation (Feb – Mar 2016). A patient enrolled in study moment 1 may not be enrolled in study moment 2. No patient will be prospectively followed-up during the study. Investigators participating in this non-interventional study will be diabetologists in outpatient settings, as this group of specialists treats most of the T2DM patients in Bulgaria.
Location
Location
Sofia, Bulgaria
Location
Pleven, Bulgaria
Location
Stara Zagora, Bulgaria
Arms | Assigned Interventions |
---|---|
Patient group in moment 1 of evaluation Study group enrolled in moment 1 of evaluation (Feb – Mar 2015) | - |
Patient group in moment 2 of evaluation Study group enrolled in moment 2 of evaluation (Feb – Mar 2016) - 1 year distance from moment 1 | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.